Immunic Stock Performance
| IMUX Stock | USD 1.02 0.03 3.03% |
The company retains a Market Volatility (i.e., Beta) of 0.66, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Immunic's returns are expected to increase less than the market. However, during the bear market, the loss of holding Immunic is expected to be smaller as well. At this point, Immunic has a negative expected return of -0.26%. Please make sure to check out Immunic's jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if Immunic performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Immunic has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 106.7 M |
Immunic |
Immunic Relative Risk vs. Return Landscape
If you would invest 120.00 in Immunic on November 3, 2024 and sell it today you would lose (22.50) from holding Immunic or give up 18.75% of portfolio value over 90 days. Immunic is currently does not generate positive expected returns and assumes 4.0046% risk (volatility on return distribution) over the 90 days horizon. In different words, 35% of stocks are less volatile than Immunic, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Immunic Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Immunic's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Immunic, and traders can use it to determine the average amount a Immunic's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0653
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IMUX |
Estimated Market Risk
| 4.0 actual daily | 35 65% of assets are more volatile |
Expected Return
| -0.26 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.07 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Immunic is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Immunic by adding Immunic to a well-diversified portfolio.
Immunic Fundamentals Growth
Immunic Stock prices reflect investors' perceptions of the future prospects and financial health of Immunic, and Immunic fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Immunic Stock performance.
| Return On Equity | -2.16 | ||||
| Return On Asset | -0.91 | ||||
| Current Valuation | 31.01 M | ||||
| Shares Outstanding | 90.08 M | ||||
| Price To Earning | (6.65) X | ||||
| Price To Book | 2.16 X | ||||
| EBITDA | (99.11 M) | ||||
| Cash And Equivalents | 72.77 M | ||||
| Cash Per Share | 1.85 X | ||||
| Total Debt | 1.33 M | ||||
| Debt To Equity | 0.01 % | ||||
| Book Value Per Share | 0.46 X | ||||
| Cash Flow From Operations | (70.83 M) | ||||
| Earnings Per Share | (1.23) X | ||||
| Total Asset | 54.3 M | ||||
| Retained Earnings | (410.89 M) | ||||
| Current Asset | 32.33 M | ||||
| Current Liabilities | 4.73 M | ||||
About Immunic Performance
Evaluating Immunic's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Immunic has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Immunic has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. t and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 65 people.Things to note about Immunic performance evaluation
Checking the ongoing alerts about Immunic for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Immunic help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Immunic generated a negative expected return over the last 90 days | |
| Immunic has some characteristics of a very speculative penny stock | |
| Immunic has high historical volatility and very poor performance | |
| Net Loss for the year was (93.61 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Immunic currently holds about 72.77 M in cash with (70.83 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.85, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Immunic has a frail financial position based on the latest SEC disclosures | |
| Roughly 65.0% of the company shares are owned by institutional investors |
- Analyzing Immunic's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Immunic's stock is overvalued or undervalued compared to its peers.
- Examining Immunic's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Immunic's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Immunic's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Immunic's stock. These opinions can provide insight into Immunic's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Immunic Stock Analysis
When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.